Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome

Bone Marrow Transplantation

Volumn 47, Issue 3, 2012, Pages 374-379

  Kim, D Y ^a   Lee, J H ^a   Park, Y H ^a   Kim, S D ^a   Choi, Y ^a   Lee, S B ^a   Lee, K H ^a,a   Ahn, S Y ^a   Lee, Y S ^a   Seol, M ^a   Kang, Y A ^a   Jeon, M ^a   Jung, A R ^a   Lee, Y J ^a  

^a Asan Medical Center   (South Korea)

Author keywords

allogeneic hematopoietic cell transplantation; azacitidine; bridging therapy; decitabine; hypomethylating therapy; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUSULFAN; FLUDARABINE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; STEM CELL MOBILIZATION; SYNDROME DELINEATION; THERAPY EFFECT; VEIN OCCLUSION;

EID: 84858071500     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.86     Document Type: Article

References (24)

1. Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS et al. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Ann Hematol 2010; 89: 15-23.
2. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421 8921 and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903. (Pubitemid 46630737)
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
4. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
5. Wijermans P, Suciu S, Baila L, Platzbecker U, Giagounidis A, Selleslag D et al. low dose decitabine versus best supportive care in elderly patients with intermediate or high riskMDS not eligible for intensive chemotherapy: final results of the randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood 2008; 112: 90.
6. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57. (Pubitemid 46053042)
7. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M et al. Low-dose 5-aza-20-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-962. (Pubitemid 30123770)
8. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-20-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: 1-5. (Pubitemid 27065040)
9. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842-3848.
10. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
11. Melchert M, List A. Targeted therapies in myelodysplastic syndrome. Semin Hematol 2008; 45: 31-38.
12. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 2009; 43: 597-609.
13. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2(Suppl 1): S24-S29.
14. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood 2001; 97: 2823-2829.
15. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemialeukemia cells by cytarabine and 5-aza-2′- deoxycytidine. Lancet 1984; 2: 867-868. (Pubitemid 14015488)
16. Pinto A, Zagonel V. 5-Aza-20-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7(Suppl 1): 51-60. (Pubitemid 23184801)
17. Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A et al. 5-Aza-20-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4(Suppl 3): 28-32. (Pubitemid 20110666)
18. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
19. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
20. De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009; 43: 839-843.
21. Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 255-260.
22. Lubbert M, Bertz H, Ruter B, Marks R, Claus R, Wasch R et al. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/ AML patients. Bone Marrow Transplant 2009; 44: 585-588.
23. Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010; 8: 40-46.
24. Lee JH, Lee JH, Lim SN, Kim DY, Kim SH, Lee YS et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant 2010; 45: 450-457.